ストックスクリーナーアプリを入手
0.4505
2.68%
-0.0124
Atyr Pharma Inc (ATYR) 最新ニュース
aTyr Pharma Ord Shs (LIFE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
aTyr Pharma Inc (ATYR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
aTyr Pharma Inc (ATYR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
aTyr Pharma Inc (ATYR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
aTyr Pharma Inc (ATYR) Valuation: PE, PB & Fair Value Analysis - TradingKey
aTyr Pharma Ord Shs (LIFE) Institutional Confidence - TradingKey
aTyr Pharma Inc (ATYR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
aTyr Pharma Inc (ATYR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
aTyr Pharma Inc (ATYR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
aTyr Pharma Inc (ATYR) Institutional Confidence - TradingKey
aTyr Pharma Ord Shs (LIFE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FMR LLC Significantly Reduces Holdings in aTyr Pharma Inc - GuruFocus
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
aTyr Pharma Company Profile & Introduction - Moomoo
aTyr Pharma Granted Nasdaq Extension to Regain Compliance - The Globe and Mail
Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide - simplywall.st
aTyr Pharma Received Notice of Noncompliance - TradingView
aTyr Pharma (NASDAQ: ATYR) wins second Nasdaq deadline to fix sub-$1 share price - Stock Titan
aTyr Pharma (ATYR) Faces Steep Decline as Shares Test Key Support ZoneJelly Roll Trade - lwvtexas.org
FMR LLC discloses 5.94M-share stake in ATYR (NASDAQ: ATYR) Amendment No.14 - Stock Titan
aTyr Pharma Inc stock (US53227K1025): shares ease after efzofitimod Phase III plan and major holder - AD HOC NEWS
Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis - TipRanks
aTyr Pharma (ATYR) Price Target Decreased by 37.13% to 6.48 - MSN
aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data - TipRanks
aTyr Pharma (ATYR) refocuses efzofitimod after EFZO-FIT miss with new Phase 3 sarcoidosis trial - Stock Titan
aTyr Pharma Inc stock (US53227K1025): Insider buying and price gains draw focus - AD HOC NEWS
aTYR Pharma director Paul Schimmel buys $49,630 in common stock By Investing.com - Investing.com Australia
aTYR Pharma director Paul Schimmel buys $49,630 in common stock - Investing.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Director at aTyr Pharma (NASDAQ: ATYR) adds 100K shares - Stock Titan
aTyr Pharma plans new phase 3 trial for pulmonary sarcoidosis drug - Investing.com Nigeria
aTyr Pharma (ATYR) Slips 1.22%, Approaching Key Support at $0.46Total Put Call - newsline.com
aTyr Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Provides Some Relief Amid Pipeline DevelopmentBasic EPS Analysis - newsline.com
Why Is aTyr Stock Falling Today? - MSN
aTyr Pharma (ATYR) Stock Forecast & Analyst Ratings - Moomoo
aTyr Pharma stock (US53227K1025): clinical pipeline update keeps biotech in focus - AD HOC NEWS
ATyr Pharma revamps efzofitimod path with new phase III sarcoidosis trial - MSN
Freedom Capital Markets Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $3.5 - Moomoo
ATYR Upgraded by Freedom Broker -- Price Target Raised to $3.50 - GuruFocus
ATyr Pharma Raised to Buy From Hold by Freedom Broker - Moomoo
ATyr Pharma Price Target Raised to $3.50/Share From $1.00 by Freedom Broker - Moomoo
aTyr Pharma upgraded to Buy from Hold at Freedom Broker - TipRanks
Freedom Broker upgrades ATYR Pharma (ATYR) - MSN
Atyr plans new global clinical trial of efzofitimod in pulmonary sarcoidosis - Sarcoidosis News
aTyr Pharma stock (US0021202025): fresh quarterly loss keeps biotech in focus - AD HOC NEWS
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Number of shareholders of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Number of shareholders of aTyr Pharma, Inc. – LS:A2PM86 - TradingView
aTyr Pharma Inc stock (US53227K1025): biotech under pressure as short interest jumps and earnings su - AD HOC NEWS
JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating - Moomoo
[10-Q] aTYR PHARMA INC Quarterly Earnings Report - Stock Titan
aTyr: Advancing Efzofitimod for Pulmonary Sarcoidosis - GuruFocus
aTyr Pharma Inc options imply 30.5% move in share price post-earnings - TipRanks
aTyr Pharma Reports Q1 2026 Results, Advances Efzofitimod Phase 3 for Pulmonary Sarcoidosis After FDA Meeting - Minichart
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):